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Abstract
Background: Pifithrin-α is a small molecule inhibitor of p53 transcriptional activity. It has been
proposed that the use of pifithrin-α in conjunction with chemotherapeutic and radiation therapies
for cancer will reduce the side effects of these treatments in normal tissue that still contains wild
type p53. In addition, pifithrin-α provides a useful tool in the laboratory to investigate the function
of p53 in model systems.
Results: While investigating the effects of pifithrin-α on the transcriptional activity of NF-κB, we
observed a strong inhibition of reporter plasmids containing the firefly luciferase gene. Firefly
luciferase is one of the most commonly used enzymes in reporter gene assays. In contrast, no
inhibition of reporter plasmids containing Renilla luciferase or chloramphenicol acetyltransferase
was observed. The inhibition of firefly luciferase activity by pifithrin-α was observed both in vivo and
in vitro. Pifithrin-α did not inhibit firefly luciferase protein expression, but rather suppressed light
production/emission, since addition of exogenous pifithrin-α to active extracts inhibited this
activity. Furthermore, pifithrin-α also inhibited recombinant firefly luciferase protein activity.
Conclusions: Among its other biological activities, pifithrin-α is an inhibitor of firefly luciferase
activity. Caution must therefore be taken when using this compound, which has been characterised
as an inhibitor of p53 transcriptional activity, to investigate effects on gene expression using
transiently transfected reporter plasmids. Furthermore, these results demonstrate that when using
novel compounds, the choice of vectors used in the experimental procedures might be of great
importance for the correct conclusions to be made.
Background
The tumour suppressor protein, p53 is one of the most
intensively studied proteins throughout biomedical
research. Due to its central role in genome surveillance,
cell cycle arrest and apoptosis induction, compounds
affecting this protein, either re-activating it or inactivating
it, are of exceptional interest and use in the field of cancer,
Alzheimer's disease, Parkinson's disease, stroke and brain
trauma [1–3].
In recent years, a chemical inhibitor of p53, Pifithrin-
α(PFT-α), has been identified and used both in vitro and
in vivo to investigate p53 function [4]. PFT-α reversibly
inhibits p53-transcriptional activity, inhibiting p53-
induced apoptosis, cell cycle arrest and DNA-synthesis
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block [4–9]. PFT-α has been successfully used in vitro and
in vivo to protect normal cells from otherwise lethal doses
of chemo and radiotherapy [3,4,10]. PFT-α thus provides
a valuable tool for the identification of genes under the
control of p53 [10]. Despite the exciting data of these
reports, little or nothing is known about the mechanism
of action of PFT-α, although it is thought to disrupt the
nuclear transport of p53 [10]. Recently, the group that
originally discovered PFT-α, reported that this compound
also inhibits the heat shock and glucocorticoid pathways,
suggesting that it targets a commonly used protein
required for the activity of multiple transcription factors
[11].
Reporter gene assays are routinely used to study the con-
trol of transcription. This involves the coupling of reporter
enzymes such as firefly or Renilla luciferase and Chloram-
phenicol acetyltransferase to the gene promoter region of
interest. Generally, the activity of these enzymes is unaf-
fected by the treatment conditions and this is not consid-
ered when interpreting the data obtained from these
assays. However, it is known that enzymes such as luci-
ferase and β-Galactosidase are affected by certain stress
conditions such as heat shock and oxidative stress [12,13].
The fact that these enzymes can be affected by such condi-
tions can give rise to misinterpreted data and compromise
the conclusions from these assays.
In this report, we have investigated the effect of PFT-α on
different reporter genes. We find that PFT-α is a specific
inhibitor of firefly luciferase. These results indicate that
when performing functional experiments with this impor-
tant compound, an appropriate choice of vector should be
utilised. These observations also give possible insight into
the mechanism of action of PFT-α in vivo.
Results
Effects of PFT-α on p53-dependent and independent 
luciferase reporter plasmids
To determine the effects of PFT-α on p53-dependent and
-independent transcriptional activity U-2 OS human oste-
osarcoma cells, which contain wild type p53, were tran-
siently transfected with a variety of firefly luciferase
reporters. The p53-responsive reporters used were PG13
and p21-luciferase and the unrelated reporters were 3x κB
and HIV-LTR-luciferase, which are both regulated by the
NF-κB family of transcription factors. Previously, we have
shown that the PG13 and 3x κB reporters are specifically
regulated by p53 and NF-κB, even in unstimulated U-2 OS
cells where there is a basal level activity of both transcrip-
tion factors [14,15]. The p21 and HIV-LTR luciferase
reporters are not solely regulated by p53 and NF-κB, how-
ever, and so effects could result from other DNA-binding
proteins. PFT-α was added to the cells at a final concentra-
tion of 20 µM and cells were harvested 24 hours later. As
expected, PFT-α strongly downregulated p53-responsive
reporters (Figure 1A) but surprisingly inhibition of the
NF-κB regulated luciferase reporters was also observed
(Figure 1B). Further experimentation revealed a dose-
dependent inhibition of both p21-luciferase and 3x κB
luciferase by PFT-α (Fig. 1C). Since cross-talk between
these transcription factors has been previously observed
[16–19], we decided to investigate if this was an effect
seen due to PFT-α mediated inhibition of p53. Using U-2
OS cells, p53 was induced by co-transfection of an expres-
sion plasmid encoding the tumour suppressor p14ARF, in
the presence or absence of PFT-α (Figure 1D). As expected,
PFT-α treatment induced p53 stabilisation and repressed
p53-induced endogenous p21 expression (Figure 1D). In
contrast, the effects on NF-κB dependent gene expression
were conflicting. While PFT-α inhibited the IκB-α luci-
ferase reporter, no effect on induction of endogenous IκB-
α protein could be detected following RelA (p65) transfec-
tion (Figure 1E &1F). Furthermore, no changes in NF-κB
DNA-binding were observed (data not shown). This
prompted us to investigate the effect of PFT-α on other
firefly luciferase reporters. These included the Cyclin D1,
Cyclin E and Bcl-2 promoters and Gal4 fusions with
RelA(p65) and the p300 coactivator protein [15,20,21].
Surprisingly, we observed that PFT-α inhibited the activity
of every firefly luciferase reporter utilised, regardless of the
transcription factors by which they were regulated (data
not shown). PFT-α is not a general inhibitor of transcrip-
tion, however, since the PFT-α treated cells did not die
(data not shown) and PFT-α had no effect on an in vitro
transcription assay (L.M. Elsby and S.G.E. Roberts, per-
sonal communication). Furthermore, it had no effect on
in vitro translation using reticulocyte lysates (data not
shown).
PFT-α does not inhibit Renilla luciferase or CAT based 
reporters
We next wanted to determine if PFT-α-mediated inhibi-
tion was also observed using chloramphenicol acetyl-
transferase (CAT) reporters or a different type of
luciferase. To investigate this, different cell types were
transiently transfected with pRL-CMV luciferase, where
the luciferase gene is from Renilla reniformis. Interestingly
PFT-α had no effect on Renilla luciferase activity (Figure
2A). Furthermore, no inhibition was observed when NF-
κB-dependent CAT-reporters were used (Figure 2B). Using
a 2x κB CAT reporter, no inhibition following PFT-α was
observed, while 3x κB-luciferase, was strongly repressed
(compare Figure 1B with Figure 2B). Similar results were
found when A20 CAT was compared to A20-luciferase fol-
lowing PFT-α treatment (data not shown).
PFT-α inhibits firefly luciferase in vitro
The results described above led us to investigate the effects
of PFT-α on firefly luciferase in vitro. Using protein extractsBMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/9
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PFT-α inhibits both p53-dependent and -independent firefly luciferase reporters Figure 1
PFT-α inhibits both p53-dependent and -independent firefly luciferase reporters. (A) PFT-α inhibits p53-dependent luciferase 
reporter plasmids. U-2 OS cells were transfected with 1.5 µg of the indicated reporters and treated with 20 µM PFT-α for 24 
hours. Cells were harvested and luciferase activity was measured and normalised for total protein. Results are expressed as 
fold repression above untreated transfected cells, and represent mean plus standard deviation of a minimum of 3 independent 
experiments. (B) PFT-α inhibits NF-κB-dependent luciferase reporter plasmids. U-2 OS cells were treated as (A) but trans-
fected with 1.5 µg of 3x κB and HIV-LTR luciferase reporter plasmids. (C) PFT-α inhibition of luciferase activity is dose 
dependent. U-2 OS cells were transfected with 1.5 µg of the indicated reporter plasmids and treated with the indicated con-
centrations of PFT-α for 24 hours. Cells were harvested and luciferase activity was measured and normalised for total protein. 
Results are expressed as fold repression above untreated transfected cells, and represent mean plus standard deviation of a 
minimum of 3 independent experiments. (D) PFT-α stabilises p53 protein and inhibits p53-dependent endogenous gene 
expression. p53 was induced in U-2 OS cells by co-transfection of 1.5 µg of ARF expression plasmid in the presence or absence 
of PFT-α, for 24 hours. Nuclear protein levels were prepared and analysed by western blot using the indicated anti-p53 and 
anti-p21 antibodies. (E) PFT-α inhibits NF-κB-dependent IκB-α reporter gene activity. HEK293 cells were co-transfected with 
1.5 µg of IκB-luciferase and 1.5 µg of RSV-p65 or empty vector. Cells were then treated with 20 µM PFT-α for 24 hours after 
which cells were harvested and luciferase activity was measured. (F) PFT-α does not inhibit induction of endogenous IκB-α. 
Western blot analysis of endogenous IκB-α using whole cell lysates from cells subjected to equivalent conditions as the luci-
ferase assay in (E).BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/9
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from human foreskin fibroblast (HFF) cells transiently
transfected with PG13 luciferase reporter plasmid, we
exogenously added different dilutions of PFT-α and ana-
lysed their activity in a luminometer (Figure 3A). Increas-
ing concentrations of PFT-α induced a dose dependent
reduction in the light emission from these extracts (Figure
3A). These results were comparable to the dose dependent
decrease observed when PFT-α was added to living cells
transfected with firefly luciferase reporter plasmids (Fig-
ure 1C). Confirming these observations, light production/
emission was also totally abolished when recombinant,
purified, firefly luciferase was treated with PFT-α in vitro
(Figure 3B). We also observed that recombinant purified
luciferase activity was inhibited by PFT-α independently
of substrate and enzyme concentration, suggesting a non-
competitive mechanism of action (Figure 3C and data not
shown). A more accurate analysis was not possible since
our equipment only measured total and not the rate of
light emission. It can therefore be concluded that PFT-α
inhibits the production/emission of light and not the
expression of active luciferase.
Discussion
The use of reporter gene assays has become a valuable tool
in investigating promoter and gene activity both in vitro
and in vivo. These assays rely on the expression and activity
of enzymes that are not naturally expressed in mamma-
lian systems and therefore should not be affected by
PFT-α does not inhibit Renilla luciferase or CAT reporters in vivo Figure 2
PFT-α does not inhibit Renilla luciferase or CAT reporters in vivo. (A) PFT-α does not inhibit Renilla luciferase. The indicated 
cell lines were transfected with 1.5 µg of pRL-CMV-luciferase reporter and treated with 20µM PFT-α for 24 hours. Cells were 
harvested and luciferase activity was measured and normalised for total protein. Results are expressed as fold repression 
above untreated transfected cells, and represent mean plus standard deviation of a minimum of 3 independent experiments. (B) 
PFT-α does not inhibit CAT reporter plasmids. U-2 OS cells were transfected with 5 µg of indicated reporters and treated 
with 20 µM PFT-α for 24 hours. Cells were harvested and CAT activity was measured and normalised for total protein. 
Results are expressed as percentage of conversion. Since there was a significant variation in the levels of activity of these 
reporters even in unstimulated conditions, although the overall conclusions were the same, the data is presented is a single 
experiment representative of 3 independent experiments.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/9
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PFT-α inhibits active and recombinant firefly luciferase Figure 3
PFT-α inhibits active and recombinant firefly luciferase. (A) Exogenously added PFT-α inhibits cell extracts containing luciferase 
activity in vitro. HFF cells were transiently transfected with 1.5 µg of PG13 reporter plasmid. Cellular extracts were obtained, 
serial dilutions of PFT-α were added as indicated, and luciferase activity was measured. Results are expressed as the mean plus 
standard deviation of a minimum of 3 independent experiments. (B) PFT-α inhibits the activity of purified recombinant luci-
ferase protein. Recombinant firefly luciferase was incubated with luciferase substrate in the presence or absence of 20 µM PFT-
α and luciferase activity was measured. Results are expressed as light units, and represent mean plus standard deviation of a 
minimum of 3 independent experiments. Error bars are beneath the resolution of the graph and although calculated, cannot be 
seen. (C) PFT-α inhibits the activity of purified recombinant luciferase protein independently of substrate concentration. 
Recombinant firefly luciferase was incubated with increasing concentrations of luciferase substrate in the presence or absence 
of 20 µM PFT-α and luciferase activity was measured. Results are expressed as light units, and represent mean plus standard 
deviation of a minimum of 3 independent experiments. Luciferase substrate concentration is not provided by the manufacturer 
(Promega) and therefore is expressed as µl of substrate used.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/9
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endogenous or exogenous conditions. The enzymes used
for reporter gene assays include luciferase (firefly and
Renilla), β-Galactosidase and CAT. These reporter gene
assays are often used to investigate the effects of novel
compounds on gene or transcription factor activity. One
of these compounds is the p53 inhibitor PFT-α which has
proven to be a valuable tool in this field of research [4–
10]. While investigating the effects of PFT-α, we found
that this compound inhibited not only p53-responsive
firefly luciferase reporters but also all other firefly luci-
ferase reporters we tested (Figure 1A,1B,1C and data not
shown). Further investigation revealed that although PFT-
α inhibited p53 transcriptional activity, as previously
described, it had no effect on endogenous levels of other
genes, such as IκB-α, while repressing luciferase promoter
activity of this gene when fused to firefly luciferase (Figure
1D,1E,1F). In addition, PFT-α also inhibited the activity
of a chromosomally integrated luciferase reporter, indicat-
ing that it was not interfering with the stability of the
reporter plasmid itself (data not shown). Additional
experiments showed that PFT-α did not inhibit Renilla
luciferase based reporters or CAT-based reporter plasmids
(Figure 2A &2B). These results suggested specific inhibi-
tion of either firefly luciferase expression or activity. It has
been recently reported that proteasome inhibitors can
inactivate both firefly luciferase and β-Galactosidase activ-
ity [22]. In this report, the proteasome inhibitors were
shown to prevent luciferase and β-Galactosidase protein
expression. In our report, this is not the case since PFT-α
inhibits active luciferase containing extracts (Figure 3A)
and purified recombinant luciferase protein (Figure 3B).
The exact mechanism of this inhibition is unknown,
although our results suggest a non-competitive mode of
action (Figure 3C). It is interesting to note that reporter
enzymes such as firefly luciferase have also been shown to
be inhibited by other compounds such as the general
anaesthetic, bromoform [23]. It was demonstrated that
anaesthetics inhibit firefly luciferase by competing with
the hydrophobic substrate and not by interfering with the
catalytic mechanism [23,24]. This could be a possible
mechanism for PFT-α mediated inhibition of firefly luci-
ferase although further investigations will be required to
verify this hypothesis. The recent report concerning PFT-α
inhibition of the heat shock and glucocorticoid signalling
pathways might also provide some insights as to the
mechanism of action of this compound [11]. It is
interesting to observe that in this study, the authors relied
on CAT based reporter gene assays and not luciferase.
When CAT reporter plasmids were used, we did not
observe inhibition of NF-κB activity (Figure 2B). Our pre-
liminary data indicates that PTF-α does inhibit a p53
driven CAT reporter (data not shown). This indicates that
PFT-α is at least a relatively selective inhibitor of gene
expression and could be used to probe the endogenous
activities of specific transcriptional regulators provided
the correct experimental system is chosen. In particularly
troublesome cases, Slot blots, Northern blots or quantita-
tive PCR could be used to assay expression of the reporter
gene.
Conclusions
These results, taken together with those from other groups
where small molecules have been found to inhibit luci-
ferase activity [22,23] indicate the importance of using
strictly controlled experiments when using reporter gene
assays and novel compounds. These effects might be of
particular relevance when designing cell based assays for
small molecule inhibitors of specific signalling and tran-
scriptional regulatory pathways.
Methods
Cell Culture
Human embryonic kidney (HEK) 293, human osteosar-
coma U-2 OS and human foreskin fibroblast (HFF) cells
were maintained at 5% CO2 in Dulbeccos Modified Eagle
Medium (DMEM) (Sigma), supplemented with 10% FCS,
1% L-glutamine (GibcoBRL) and 1% penicillin/strepto-
mycin (Sigma).
Reporter Plasmid and expression plasmids
Firefly (Photinus pyralis) Luciferase reporter plamids used
were: 3x κB-luc and IκB-α-luc (provided by Prof. Ron Hay,
St. Andrews), PG13-luc and p21-luc (provided by Prof.
David Lane, Dundee and Dr. Tim Crook, London). Renilla
(Renilla reniformis) Luciferase reporter plasmid pRL-CMV
was obtained from Promega. CAT reporter plasmids: 2x
κB and A20 CAT have been described previously [14,16].
The RSV-p65 expression plasmid has also been described
[16]. The pCDNA3 p14ARF expression plasmid was pro-
vided by Dr Gordon Peters (London).
Luciferase Reporter Assays
For analysis of luciferase reporters, cells were plated in 6-
well plates and transiently transfected using the Calcium
Phosphate method (previously described in [16]). Luci-
ferase activity was determined using the Luciferase assay
system (Promega) according to the manufacturer's
instructions and normalised for total protein. Quan-
tiLum®  Recombinant Luciferase was obtained from
Promega and light units were determined according to
manufacturer's instructions.
CAT Reporter Assays
Indicated cells were plated in 100 mm dishes, transfected
by Calcium phosphate method and analysed as previ-
ously described [16]. Results were normalised for total
protein.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/9
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PFT-α Treatments
PFT-α was obtained from Biomol and dissolved in
DMSO. For in vivo studies, PFT-α or the equivalent
amount of DMSO in controls, were added directly to cells
at the final concentrations indicated. For in vitro studies,
PFT-α was added exogenously to active cellular extracts or
recombinant luciferase and compared to an equivalent
DMSO treatment.
Protein Extraction, Western Blot Analysis and Antibodies
Nuclear extracts were prepared as described previously
[25]. For whole protein lysates, cells were washed once
with PBS, and resuspended in buffer A (20 mM Hepes pH
7.6, 400 mM NaCl, 1 mM EDTA, 25% Glycerol, 0.1% NP-
40, 1 mM DTT). Cells were lysed with 10 strokes of a 26 G
syringe. Cells were incubated on ice for 30 minutes before
centrifugation at maximum speed for 15 minutes. All
solutions used in protein extractions contained protease
and phosphatase inhibitors, PMSF (1 mM), leupeptin (1
µg/µl), aprotinin (1 µg/µl), pepstatin A (1 µg/µl), NaF (5
mM), Na3VO4  (500  µM). Protein determination of
extracts was performed using the BioRad Bradford protein
assay. Following SDS-PAGE, resolved proteins were elec-
troblotted onto PVDF membranes. The membrane was
blocked in 10% blocking buffer (TBS-0.1% Tween-20,
10% milk) for 30 minutes. The membrane was then
probed with the primary antibody in 5% TTBS-milk over-
night at 4°C, followed by three 10 minute washes with
TTBS. Incubation with the secondary antibody was per-
formed for 1 hour at room temperature followed by 3
times 10 minutes washes with TTBS. Detection of proteins
was achieved using ECL (Amersham).
Antibodies used were anti-p21 (Santa Cruz Biotechnol-
ogy), anti-p53 DO-1 (gift from Dr. Sonia Lain and Prof.
David Lane, Dundee) and anti-IκB-α (gift from Prof.
Nancy Rice, National Cancer Institute). All of these anti-
bodies have been previously described [20].
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